FLAG方案治疗难治/复发性急性髓细胞白血病的临床观察

摘要

objective:to observe the fluorine dara marina (Flud) joint cytarabine (Ara-C), recombinant human granulocyte colony stimulating factor (g-csf) FLAG regimen for refractory/recurrent acute myelogenous leukemia clinical curative effect and adverse reaction. Methods:using fluorine dara marina (Flud) 50 mg/d, intravenous drip, lasts 30 min, d1-d5;Cytarabine (Ara-C) 2 g/d, 4 h after using Flud drip into the, last 3 h d1-d5;Recombinant human granulocyte colony stimulating factor (g-csf) 300 ug/d, hypodermic d0-d5, FLAG was used in treatment of refractory or recurrent acute myelogenous leukemia treatment of 17 cases, the curative effect and adverse reaction was observed. Conclusion:17 cases with complete remission in 11 cases, complete response rate was 64.7%, partial in 3 cases, persist in 1 case, 2 cases died, the effective rate was 82.4%. Main side effects for bone marrow inhibition, infection, gastrointestinal symptoms and mild liver damage. Conclusion:treat/FLAG regimen for recurrent acute myelogenous leukemia is safe and effective.%目的：观察氟达拉滨（Flud）联合阿糖胞苷(Ara-C)、重组人粒细胞集落刺激因子（G-CSF）组成的FLAG方案治疗难治/复发性急性髓细胞白血病的临床疗效及主要毒副反应。方法：采用氟达拉滨（Flud）50mg/d,静脉滴入，持续30min,d1-d5；阿糖胞苷(Ara-C)2g/d，用Flud后4h滴入，持续3h d1-d5；重组人粒细胞集落刺激因子（G-CSF）300ug/d,皮下注射d0-d5，采用FLAG方案治疗难治/复发性急性髓细胞白血病治疗17例，观察其疗效及毒副反应。结论：17例患者完全缓解11例，完全缓解率为64.7%，部分缓解3例，未缓解1例，死亡2例，有效率82.4%。主要副反应为骨髓抑制、感染、消化道症状、轻度肝损害。结论：FLAG方案治疗治/复发性急性髓细胞白血病安全有效。